Original Research Article|Articles in Press, 110055

Implications of using home urine pregnancy tests versus facility-based tests for assessment of outcome following medication abortion provided via telemedicine



      To assess whether planning high-sensitivity urine pregnancy tests (HSPT) rather than facility-based tests for medication abortion follow-up may increase risk of unplanned clinical visits or procedural completion of the abortion.

      Study design

      We used data from the TelAbortion Project, a 5-year study assessing the safety and feasibility of providing mifepristone and misoprostol by telemedicine and mail in the United States. We categorized participants by whether the pretreatment follow-up plan included HSPT at home 3–5 weeks after treatment or facility-based tests (ultrasound or serum human chorionic gonadotropin) within 2 weeks after treatment. We used multivariable logistic regression to compare likelihood of post-treatment unplanned, abortion-related clinical visits and procedural intervention in these groups.


      Of 1324 patients who planned HSPT follow-up and 576 who planned facility-based tests, 85% and 83%, respectively, provided outcome information. Post-treatment clinical visits were less frequent in the HSPT group (19%) than in the facility-based test group (79%); most of the latter were to obtain the planned test. However, unplanned, abortion-related visits were significantly more common in the HSPT group (adjusted risk difference: 6.5%; p < 0.01). The likelihood of procedural completion did not differ by group. Planned follow-up test was not associated with delay in procedural completion or detection of ongoing pregnancy.


      Follow-up of medication abortion with home HSPT was associated with fewer post-treatment clinical visits, modestly more unplanned, abortion-related clinical visits, and no increase in the risk of procedural interventions or delayed identification or management of treatment failures. This option is an appropriate follow-up approach after medication abortion.


      Use of home high-sensitivity pregnancy tests rather than facility-based tests for outcome assessment after medication abortion is associated with a modest increase in unplanned clinical visits but does not lead to an increase in procedural interventions or delays identification and management of treatment failure.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Flynn A.N.
        • Lerma K.
        Update on medication abortion follow-up options: many sizes to fit all.
        Curr Opin Obstet Gynecol. 2022; 34: 379-385
        • Sheele J.M.
        • Bernstein R.
        • Counselman F.L.
        A ruptured ectopic pregnancy presenting with a negative urine pregnancy test.
        Case Rep Emerg Med. 2016; 20167154713
        • National Abortion Federation
        Clinical policy guidelines. National Abortion Federation, Washington, DC2020
        • American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Gynecology
        • Society of Family Planning
        Medication abortion up to 70 days of gestation: ACOG practice bulletin, number 225.
        Obstet Gynecol. 2020; 136: e31-e47
        • Raymond E.G.
        • Anger H.A.
        • Chong E.
        • Haskell S.
        • Grant M.
        • Boraas C.
        • et al.
        “False positive” urine pregnancy test results after successful medication abortion.
        Contraception. 2021; 103: 400-403
        • Chong E.
        • Shochet T.
        • Raymond E.
        • Platais I.
        • Anger H.A.
        • Raidoo S.
        • et al.
        Expansion of a direct-to-patient telemedicine abortion service in the United States and experience during the COVID-19 pandemic.
        Contraception. 2021; 104: 43-48
        • Raymond E.
        • Chong E.
        • Winikoff B.
        • Platais I.
        • Mary M.
        • Lotarevich T.
        • et al.
        TelAbortion: evaluation of a direct to patient telemedicine abortion service in the United States.
        Contraception. 2019; 100: 173-177
        • Anger H.A.
        • Raymond E.G.
        • Grant M.
        • Haskell S.
        • Boraas C.
        • Tocce K.
        • et al.
        Clinical and service delivery implications of omitting ultrasound before medication abortion provided via direct-to-patient telemedicine and mail in the U.S.
        Contraception. 2021; 104: 659-665
        • Hernan M.A.
        • Robins J.
        Standardization and the parametric g-formula. Causal inference: what if. Chapman and Hill/CRC, Boca Raton2020: 161-169
        • Hernan M.A.
        • Robins J.
        IP weighting and marginal structural models. Causal inference: what if. Chapman and Hill/CRC, Boca Raton2020: 149-160
        • Perriera L.K.
        • Reeves M.F.
        • Chen B.A.
        • Hohmann H.L.
        • Hayes J.
        • Creinin M.D.
        Feasibility of telephone follow-up after medical abortion.
        Contraception. 2010; 81: 143-149
        • Chen M.J.
        • Rounds K.M.
        • Creinin M.D.
        • Cansino C.
        • Hou M.Y.
        Comparing office and telephone follow-up after medical abortion.
        Contraception. 2016; 94: 122-126